This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 834,513 Years Active: 2004
Title: Marjan J W Visseren: Innovator in Tumor Rejection Antigens
Introduction
Marjan J W Visseren is a notable inventor based in Leiden, Netherlands. He has made significant contributions to the field of immunology, particularly in the development of isolated peptides derived from mage tumor rejection antigen precursors.
Latest Patents
Visseren holds a patent for "Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules." This innovative work focuses on the complexes of SEQ ID NO: 12 and HLA-A2, which can be utilized to generate cytotoxic T lymphocytes (CTLs). Furthermore, these complexes can be supplemented with interleukin-6 (IL-6) and interleukin-12 (IL-12) to enhance their effectiveness.
Career Highlights
Throughout his career, Visseren has demonstrated a commitment to advancing cancer immunotherapy. His research has the potential to improve treatment options for patients with tumors that express specific antigens.
Collaborations
Visseren has collaborated with esteemed colleagues, including Alan Townsend and Judy Bastin, who have contributed to his research endeavors.
Conclusion
Marjan J W Visseren's work in the field of tumor rejection antigens exemplifies the innovative spirit of modern science. His contributions are paving the way for new therapeutic strategies in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile